Publication:
Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.

Loading...
Thumbnail Image

Date

2019-04-04

Authors

Philis-Tsimikas, Athena
Billings, Liana K
Busch, Robert
Portillo, Cristobal Morales
Sahay, Rakesh
Halladin, Natalie
Eggert, Sarah
Begtrup, Kamilla
Harris, Stewart

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as add-on to sodium-glucose co-transporter-2 (SGLT2) inhibitor therapy. In this 26-week, phase IIIb, open-label, parallel-group, treat-to-target trial, conducted at 74 sites in 11 countries, insulin-naïve people aged ≥18 years with glycated haemoglobin (HbA1c) 53-97 mmol/mol (7.0-11.0%), body mass index 20-40 kg/m2 and inadequately controlled type 2 diabetes (T2D) on SGLT2 inhibitor ± oral antidiabetic drugs were randomized 1:1 to once-daily IDegLira or IGlar U100, both as add-on to existing therapy. The primary endpoint was change in HbA1c from baseline to week 26. A total of 210 participants were randomized to each treatment arm. Mean HbA1c reductions were 21 mmol/mol (1.9%-points) with IDegLira and 18 mmol/mol (1.7%-points) with IGlar U100; confirming non-inferiority (P  The favourable safety and efficacy profile of IDegLira in people with uncontrolled T2D on SGLT2 inhibitors, and lower weight gain and hypoglycaemia risk versus IGlar U100, suggest that clinicians should consider IDegLira initiation in this population.

Description

MeSH Terms

Aged
Diabetes Mellitus, Type 2
Drug-Related Side Effects and Adverse Reactions
Female
Glycated Hemoglobin
Humans
Hypoglycemic Agents
Insulin, Long-Acting
Liraglutide
Male
Middle Aged
Sodium-Glucose Transporter 2 Inhibitors

DeCS Terms

CIE Terms

Keywords

GLP-1 analogue, SGLT2 inhibitor, insulin therapy, liraglutide, randomized trial, type 2 diabetes

Citation